Evidence map›Paper›PMID 33870441›Full record

ReviewApoptosis : an international journal on programmed cell death2021

Forcing dividing cancer cells to die; low-dose drug combinations to prevent spindle pole clustering.

Eloise Ducrey, Cédric Castrogiovanni, Patrick Meraldi, Patrycja Nowak-Sliwinska

Open access · hybridAbstract readReview
In one paragraph

Review in Apoptosis : an international journal on programmed cell death, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Eloise DucreySchool of Pharmaceutical Sciences, Faculty of Sciences, University of Geneva, Rue Michel-Servet 1, CMU, 1211, Geneva 4, Switzerland.
Cédric CastrogiovanniTranslational Research Center in Oncohaematology, Rue Michel-Servet 1, CMU, 1211, Geneva 4, Switzerland.
Patrick MeraldiTranslational Research Center in Oncohaematology, Rue Michel-Servet 1, CMU, 1211, Geneva 4, Switzerland. Patrick.Meraldi@unige.ch.
Patrycja Nowak-SliwinskaSchool of Pharmaceutical Sciences, Faculty of Sciences, University of Geneva, Rue Michel-Servet 1, CMU, 1211, Geneva 4, Switzerland. Patrycja.Nowak-Sliwinska@unige.ch.ORCID http://orcid.org/0000-0002-8299-0444
University of Geneva · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mitosis, under the control of the microtubule-based mitotic spindle, is an attractive target for anti-cancer treatments, as cancer cells undergo frequent and uncontrolled cell divisions. Microtubule targeting agents that disrupt mitosis or single molecule inhibitors of mitotic kinases or microtubule motors kill cancer cells with a high efficacy. These treatments have, nevertheless, severe disadvantages: they also target frequently dividing healthy tissues, such as the haematopoietic system, and they often lose their efficacy due to primary or acquired resistance mechanisms. An alternative target that has emerged in dividing cancer cells is their ability to "cluster" the poles of the mitotic spindle into a bipolar configuration. This mechanism is necessary for the specific survival of cancer cells that tend to form multipolar spindles due to the frequent presence of abnormal centrosome numbers or other spindle defects. Here we discuss the recent development of combinatorial treatments targeting spindle pole clustering that specifically target cancer cells bearing aberrant centrosome numbers and that have the potential to avoid resistance mechanism due their combinatorial nature.

Indexed as

Antineoplastic AgentsCell DeathCentrosomeDrug CombinationsDrug SynergismHistone Deacetylase InhibitorsHumansMitosisNeoplasmsProtein Kinase InhibitorsSpindle PolesAntineoplastic AgentsDrug CombinationsHistone Deacetylase InhibitorsProtein Kinase InhibitorsCancerCentrosome clusteringDrug combinationMitosis

Identifiers

PMID33870441
PMCPMC8197716
OpenAlexW3155811702

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.